Telomerase and HER-2/ neu as targets of genetic cancer vaccines in dogs

Abstract Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior an...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2010-02, Vol.28 (5), p.1201-1208
Main Authors: Peruzzi, Daniela, Mesiti, Giuseppe, Ciliberto, Gennaro, La Monica, Nicola, Aurisicchio, Luigi
Format: Article
Language:English
Subjects:
Adaptive Immunity
Adenoviridae
Adenovirus
Allergy and Immunology
Animals
Applied microbiology
Biological and medical sciences
Cancer Vaccines - genetics
Cancer Vaccines - immunology
DNA-EP
Dog Diseases
Dogs
Electroporation
Female
Fundamental and applied biological sciences. Psychology
Humans
Immunization
Mammary Neoplasms, Animal - immunology
Mammary Neoplasms, Animal - prevention & control
Medical sciences
Mice
Mice, Inbred BALB C
Microbiology
Miscellaneous
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - immunology
Telomerase
Tumor immunity
Tumors
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Pet dogs represent a valuable pre-clinical model to assess the efficacy of oncology drugs. Additionally, canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior and response to conventional therapies. The telomerase reverse transcriptase (TERT) is reactivated in most of human and dog tumors. Similarly, HER-2/ neu oncoprotein is overexpressed in a proportion of canine breast cancers. Therefore, TERT and HER-2/ neu can constitute valid tumor associated antigens (TAA), suitable targets for translational cancer immunotherapy in dogs. In this study, we have evaluated the ability of DNA electroporation (DNA-EP) and Adenovirus serotype 6 (Ad6) to induce immune responses against dog TERT (dTERT) and HER-2/ neu in healthy dogs. Vaccination was effective in all treated animals and the adaptive immune response remained detectable and long-lasting in the absence of autoimmunity or other side-effects. Our results show that DNA-EP/Ad6-based cancer vaccine induces adaptive immune responses against TAA in canine subjects and support further evaluation of this approach in cancer dog patients.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.11.031